Operating signal within 12 months from two or more independent sources.
What they make
Pharmaceutical Preparation Manufacturing325412Travere Therapeutics is a biopharmaceutical company focused on rare kidney disease. It develops pegtibatinase and civorebrutinib, and its work addresses IgA Nephropathy, Focal Segmental Glomerulosclerosis, Classical Homocystinuria, and Cystinuria. The company announced U.S. FDA approval related to Focal Segmental Glomerulosclerosis.
SUMMARIZED FROM THE COMPANY’S OWN WEBSITE
Products
Recorded against the company rather than this address. Federal award and drug records name the company, not the plant, so we cannot say which of its sites makes these.
Where these came from
Where it is
Location not verified — this address could not be matched to Census TIGER, so the facility is not placed on the map.
Other plants nearby
No other listed facility within 40 km shares this one’s four-digit industry code, or this record has no coordinates to measure from.
Also at this address
No other federal record shares this street address.
WHERE THIS RECORD COMES FROM — 2 FEDERAL SOURCES, 7 FIELDS
Every fact on this page traces to a public federal filing. The table below names which register holds this facility, whether that register proves the plant operates or only that it exists, and when each of them last saw it.
| Source | Evidence | First seen | Last seen |
|---|---|---|---|
| COMPANY SITE | OPERATING | SEP 2026 | SEP 2026 |
| SAM GOV | OPERATING | DEC 2025 | DEC 2025 |
FIELD BY FIELD — WHICH SOURCE SUPPLIED WHAT
| FIELD | SOURCE | SIGNAL |
|---|---|---|
| ADDRESS LINE1 | SAM GOV | DEC 2025 |
| CAGE CODE | SAM GOV | DEC 2025 |
| CITY | SAM GOV | DEC 2025 |
| NAME | SAM GOV | DEC 2025 |
| REGISTRATION EXPIRATION | SAM GOV | DEC 2025 |
| STATE | SAM GOV | DEC 2025 |
| WEBSITE | SAM GOV | DEC 2025 |
Status is computed from independent sources; nothing here is self-reported unless marked Claimed.